Merck Drugs Cure Covid ?
Merck Drugs Cure Covid ? MERCKyBusiness – IS THE CURE WORSE THAN THE DISEASE?
Why today’s announcement that #molnupiravir cuts risk of #COVID19 hospitalization and death in half IS NOT GOOD NEWS, but a demonstration of #BigPharma murky business, or in the case of Merck, #MERCKyBusiness.
If you believe, for example, @DrEricDing, a senior fellow of the Federation of American Scientists, it is time to open our Champagne bottles. An antiviral drug can cut hospitalization and death in half in a randomized trial. Finally! It is such great news that the U.S. government already made an advance purchase of 1.7 million doses of the drug at a cost of $1.2 billion. Great news, we are being told.
LET US LOOK AT THE FACTS.
Molnupiravir (AKA MK-4482/EIDD-2801) is not really a new drug, in the sense that it is a prodrug of N4-hydroxycytidine (NHC), which means it was designed to improve the bioavailability of how it absorb, distributed, metabolized, and excreted.
“N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage”. N4-Hydroxycytidine, N(4)-Hydroxycytidine,
Beta-D-N4-hydroxycytidine, and EIDD-1931 are all synonyms.
We now know that Molnupiravir works by promoting SARS-CoV-2 mutagenesis, which means that this drug promotes the genetic information of an SARS_CoV_2 to change by the production of a mutation, and by doing so is supposed to disable it.
But what also do we know about the compound which this product is based upon?
Well, quite a number of alarming things. N4-Hydroxycytidine is TOXIC:
N4-Hydroxycytidine (NHC) “exhibits measurable levels of cytotoxicity, with 50% cytotoxic concentration values … in cell lines”
Also, “β-D-N4-hydroxycytidine (rNHC) and its orally bioavailable prodrug, molnupiravir, does inhibits SARS-CoV-2 in vitro BUT IS MUTAGENIC IN MAMALIAN CELLS…resulting in DNA mutation of dividing mammalian cells.”
And also, based on whistleblower charges of cronyism behind the drug, that “some earlier studies suggested EIDD-2801 (#molnupiravir) COULD CAUSE HARMFUL GENETIC MUTATIONS… similar experimental drugs in this class had been shown to cause reproductive toxicity in animals, and OFFSPRING FROM TREATED ANIMALS HAD BEEN BORN WITHOUT TEETH AND WITHOUT PARTS OF THEIR SKULLS”
So quick recap – a drug that can cause DNA damage, AND which is a bioavailable version what exhibits measurable levels of 50% toxicity to cells is considered to be good news that #Merck is asking for emergency authorization FOR THE WORLD?
How by looking at 775 adults who had health problems with mild-to-moderate COVID-19, and with a period of trial of 30 days which resulted in 6.8% reduction in hospitalization or death (14.1% vs 7.3%) Merck wants such authorization? How come @DrEricDing, an Epidemiologist & health economist, Senior Fellow @FAScientists, w/former 16 years @Harvard, a @JohnsHopkins alum is reporting on this drug as if we found the fountain of life? Doesn’t he care about the dangers of this drug?
I want to remind everyone that #Merck already in the past has suppressed the clinical trial evidence about the dangers of one product, #VIOXX, that led to the death of many people. The fact a medical product has one desirable effect does not allow us to ignore the other impact of that product on the body. Good example is radiation – it can kill cancer cells, but also is deadly to your body.
A drug that carries zero liability under emergency authorization = goldmine for Merck. This drug might lead to DNA damage and cytotoxicity yet “scientists”, media & regulators don’t care. We are in a post-modernism era: science is dead, long live scientism!
Take a close look at who is hailing this drug (media, “scientists”, “journalists”), and realize that THEY DO NOT CARE ABOUT YOUR HEALTH, THEY DO NOT CARE ABOUT YOU. Notice how these are the same people who have been “selling” you facemasks, lockdowns & vaccines.
#MERCKyBusiness – IS THE CURE WORSE THAN THE DISEASE?
Why today's announcement that #molnupiravir cuts risk of #COVID19 hospitalization and death in half IS NOT GOOD NEWS, but a demonstration of #BigPharma murky business, or in the case of #Merck, #MerckyBusiness.
— Ehden @ TELEGRAM CHANNEL: T.ME/EH_DEN (@eh_den) October 1, 2021
Merck & Co. said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use.
If cleared, Merck’s drug would be the first pill shown to treat COVID-19, a potentially major advance in efforts to fight the pandemic. All COVID-19 therapies now authorized in the U.S. require an IV or injection.
Merck and its partner, Ridgeback Biotherapeutics, said early results showed patients who received the drug, called molnupiravir, within five days of COVID-19 symptoms had about half the rate of hospitalization and death as patients who received a dummy pill. The study tracked 775 adults with mild-to-moderate COVID-19 who were considered higher risk for severe disease because of health problems such as obesity, diabetes or heart disease.
Among patients taking molnupiravir, 7.3 per cent were either hospitalized or died at the end of 30 days, compared with 14.1 per cent of those getting the dummy pill. There were no deaths in the drug group after that time period compared with eight deaths in the placebo group, according to Merck.
The results were released by the company and have not been peer reviewed. Merck said it plans to present them at a future medical meeting.
Health Canada has been reviewing data around molnupiravir since August as part of its rolling review of potential treatments.
Federal officials told reporters on Friday that there is no specific timeline for completing that review.
“The interest in the Merck antiviral is because of ease of use,” said chief public health officer Dr. Theresa Tam during the briefing. “And you can give it up to five days in the start of someone’s clinical course, so you have a bit of time.”
Drugmaker Merck says its experimental COVID-19 pill reduced hospitalisations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the US and around the world to authorise its use.
If cleared, the drug would be the first pill shown to treat COVID-19, a potentially major step forward in global efforts to control the pandemic. All COVID-19 therapies now authorised in the US require an IV or injection.
A pill that could be taken at home, by contrast, could keep many patients out of the hospital, easing the workload on strained health care professionals. It could also help curb outbreaks in lower-income countries that don’t have access to the more expensive infusion therapies.